AstraZeneca's Calquence Combo Cuts Progression Risk By 27% In Mantle Cell Lymphoma Trial

(RTTNews) - AstraZeneca Plc. (AZN.L) said that results from the ECHO Phase III trial showed the company's Calquence (acalabrutinib) in combination with bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in progression-free su https://www.nasdaq.com/articles/astrazenecas-calquence-combo-cuts-progression-risk-27-mantle-cell-lymphoma-trial